Mercaptopurine

證據等級: L5

預測適應症: 10 個

Mercaptopurine: From Acute Lymphoblastic Leukemia to Myeloid Leukemia

One-Sentence Summary

Mercaptopurine (6-MP) is a purine analog antimetabolite established as the global backbone of acute lymphoblastic leukemia (ALL) maintenance therapy for over six decades. The TxGNN model predicts it may be effective for Myeloid Leukemia, with 29 clinical trials and 20 publications currently supporting this direction. Historical RCTs confirm 6-MP’s activity in AML induction and APL maintenance, and two active Phase 1/2 trials are now re-evaluating 6-MP in modern AML combination regimens.

Quick Overview

Item	Content
Original Indication	Acute Lymphoblastic Leukemia (ALL) — global standard maintenance therapy
Predicted New Indication	Myeloid Leukemia
TxGNN Prediction Score	99.94%
Evidence Level	L2
Philippines Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data from DrugBank is not available in this Evidence Pack. However, based on well-established clinical pharmacology, mercaptopurine is a purine analog that is intracellularly converted to thioguanine nucleotides (TGNs) — the primary active species. TGNs are incorporated into DNA in place of natural purines, blocking DNA replication and triggering cell death. In parallel, 6-MP inhibits de novo purine biosynthesis by suppressing multiple key enzymes (PPAT, ATIC, adenylosuccinate synthetase), depleting the nucleotide pool required for rapid cell division. This dual mechanism is selectively cytotoxic to rapidly proliferating cells such as leukemic blasts.

Both ALL (where 6-MP is the maintenance backbone) and myeloid leukemia share a defining pathological feature: uncontrolled proliferation of immature hematopoietic blast cells that are highly dependent on continuous purine synthesis. While myeloid blasts differ from lymphoid blasts in lineage and surface markers, they are equally vulnerable to antimetabolite-mediated nucleotide depletion. This mechanistic overlap — rather than mere TxGNN structural inference — is supported by decades of real clinical use: 6-MP was historically incorporated into AML induction protocols (JALSG-AML92 RCT in Japan) and remains part of acute promyelocytic leukemia (APL) maintenance regimens worldwide (AIDA, PETHEMA LPA 2005, NCT00003934).

There is currently renewed clinical interest in 6-MP for myeloid disease in a new context: combination with novel agents. NCT05506332 (the ApoAML trial) directly evaluates venetoclax + 6-MP in relapsed/refractory AML based on the hypothesis that purine analog-mediated DNA damage synergizes with Bcl-2 inhibition. NCT06199557 tests 6-MP + valproic acid in AML/high-risk MDS patients unfit for intensive chemotherapy — an underserved population with few effective oral options. These trials position 6-MP not as a standalone legacy drug but as a potential partner in mechanism-based modern combinations.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00003934	Phase 3	Completed	420	Randomized APL trial directly comparing tretinoin + combination chemo with or without ATO, followed by mercaptopurine + methotrexate maintenance; establishes 6-MP/MTX as the standard APL maintenance backbone
NCT01064557	N/A	Unknown	1,068	AIDA protocol for APL (1993–2020): evaluates intermittent ATRA vs. MTX + 6-MP maintenance in PCR-negative patients; largest APL dataset incorporating 6-MP maintenance
NCT00002701	Phase 3	Unknown	750	APL Phase 3: ATRA + Idarubicin induction → intensive consolidation → randomized maintenance including 6-MP; evaluates transplant vs. chemotherapy in PCR-positive patients
NCT00408278	Phase 4	Completed	300	PETHEMA LPA 2005: risk-adapted APL protocol with ATRA + anthracycline induction/consolidation, followed by ATRA + MTX + 6-MP maintenance; evaluates mitoxantrone reduction in low/intermediate risk
NCT00136084	Phase 3	Completed	238	Multi-arm AML trial comparing two cytarabine-based induction regimens in newly diagnosed AML patients; collaborative design with 6-MP as potential maintenance component
NCT00962767	Phase 3	Completed	168	Randomized APL trial: gemtuzumab ozogamicin vs. ATRA + chemotherapy (including 6-MP) as post-consolidation maintenance in intermediate/high-risk patients
NCT00465933	Phase 4	Completed	N/A	APL AIDA protocol (1999–2007): ATRA + Idarubicin induction with dose reduction in elderly (≥70 years), MTX + mercaptopurine maintenance; also evaluates 6-MP in APL molecular/haematological relapse salvage
NCT00866918	Phase 3	Completed	106	Risk-adapted childhood APL trial using ATO during consolidation; standard maintenance phase incorporates 6-MP backbone
NCT06199557	Phase 1/2	Recruiting	48	Active trial directly testing 6-MP + valproic acid in AML/high-risk MDS patients unfit for standard induction (2024–2029); oral regimen targeting elderly/frail patients
NCT05506332	Phase 1	Recruiting	10	ApoAML trial: directly evaluates venetoclax + 6-MP (purine analog combination) in relapsed/refractory AML (2022–2026); novel mechanistic rationale combining Bcl-2 inhibition with antimetabolite

Literature Evidence

PMID	Year	Type	Journal	Key Findings
10497848	1999	RCT	Int J Hematology	JALSG-AML92 study: randomized trial of daunorubicin + behenoyl cytarabine + 6-MP (BHAC-DM) vs. BHAC-DM + etoposide in adult AML; CR ~63%; establishes 6-MP as integral component of Japanese AML induction standard
8174198	1994	RCT	Cancer Chemother Pharmacol	Nationwide Japan randomized trial (n=360): BH-AC·DMP (with 6-MP) CR 63.7% vs. BH-AC·AMP 53.9%; largest early RCT validating 6-MP-containing regimen in AML; Japan Leukemia Study Group multicenter
26425037	2015	Prospective Cohort	J Korean Med Sci	Oral 6-MP + weekly MTX maintenance for 2 years in transplant-ineligible AML patients after first CR; demonstrates improved leukemia-free and overall survival vs. no maintenance
9095207	1997	Clinical Trial	Cancer Invest	High-dose continuous IV 6-MP + intermediate-dose cytarabine in AML first remission (pediatric, n=17); 14/17 patients achieved CR; establishes feasibility of HD 6-MP intensification in AML
1793832	1991	Clinical Trial	Int J Hematology	Intensive individualized induction with behenoyl cytarabine + daunorubicin + 6-MP in 41 adult AML patients; 71% CR rate; validates 3-drug 6-MP-containing induction
1059498	1975	Clinical Trial	Cancer	18 children with AML treated with cytarabine + daunorubicin + prednisolone + mercaptopurine or thioguanine; 78% initial CR rate, 93% in protocol completers; foundational pediatric AML data
28835099	2017	In Vitro	Biomacromolecules	CD44-targeted glutathione-sensitive hyaluronic acid-6-MP prodrug nanoparticles show enhanced cytotoxicity in AML cells vs. free 6-MP; supports novel delivery strategies to overcome bioavailability limitations
24492035	2014	Review	Jpn J Clin Hematology	Japanese review of current AML/APL therapy; contextualizes 6-MP’s historical role in APL maintenance within modern ATRA + arsenic trioxide landscape
5220682	1966	Case Series	Minnesota Med	Among the earliest reports of AML treated with 6-MP + cyclophosphamide; historical documentation of 6-MP cytotoxic activity in myeloid leukemia
265178	1977	Case Series	Blood	Three juvenile CML cases showing clinical and hematologic response to sequential subcutaneous cytarabine + oral mercaptopurine; demonstrates 6-MP activity in chronic myeloid disease

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Purine analog / Thiopurine antimetabolite
Myelosuppression Risk	High — Neutropenia and thrombocytopenia are dose-limiting; risk is substantially amplified in patients with TPMT or NUDT15 loss-of-function variants (NUDT15 c.415C>T carrier frequency ~10–20% in Southeast Asian populations including Filipinos)
Emetogenicity Classification	Low
Monitoring Items	CBC with differential (weekly at treatment initiation, monthly during stable maintenance), liver function tests (ALT, AST, bilirubin — hepatotoxicity is a recognized toxicity), TPMT and NUDT15 genotyping before initiation
Handling Protection	Must follow cytotoxic drug handling regulations; wear gloves when handling tablets; do not crush or split; dispose as cytotoxic waste

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple completed Phase 3 trials directly incorporating mercaptopurine in myeloid leukemia (especially APL) maintenance regimens, combined with historical RCTs demonstrating 6-MP activity in AML induction, provide sufficient mechanistic and clinical evidence to justify further evaluation. Two active Phase 1/2 trials (NCT05506332, NCT06199557) confirm ongoing scientific interest in 6-MP for AML. However, 6-MP is not registered in the Philippines, package insert safety data is unavailable, and Asian-specific pharmacogenomic risks require mandatory pre-treatment assessment.

To proceed, the following is needed:

Philippines FDA registration or compassionate use pathway assessment
Full package insert review for complete warnings, contraindications, and drug interactions (including allopurinol — a major 6-MP interaction partner — and azathioprine co-use prohibition)
Mandatory pre-treatment TPMT and NUDT15 genotyping protocol, with standardized dose-reduction guidelines for Southeast Asian variant carriers (particularly NUDT15 c.415C>T)
Clear definition of target patient population: APL maintenance (established role), AML unfit for intensive therapy (NCT06199557 context), or relapsed/refractory AML (NCT05506332 context)
Hepatotoxicity and myelosuppression monitoring plan, with CBC and LFT frequency schedule
Confirmation of oral formulation (tablet or suspension) availability and supply chain for the Philippines
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.